Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...

Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin ...

In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...

Chronic obstructive pulmonary disease (COPD) is a lung condition that often hides in plain sight. You may think you’re dealing with a common cold, when in reality, your lungs are swollen, irritated ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...